Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

By N. Johnson, G. Slack, K. Savage, J. Connors, S. Ben-Neriah, S. Rogic, D. Scott, K. Tan, C. Steidl, L. Sehn and 21 more. Journal of Clinical Oncology, 2012

1,068 citations recorded by the source corpus.

Subfields: Neurology, Pathology and Forensic Medicine, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/62289ad71bb212789efb9297dd5fd887fd4180da

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. H. Tilly
2. Shimin Hu
3. Z. Xu-Monette
4. M. G. Silva
5. A. Tzankov
6. G. Slack
7. U. Vitolo
8. Lin Wu

Citations in the corpus

• MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. (2013, background): “With regard to the prognostic impact of BCL2 expression alone in DLBCL in the era of R-CHOP chemotherapy, previous studies reported inconsistent results.(21,23,24,37-44) Most of these studies had small patient cohorts and/or also did not address the confounding effects of other factors, such as MYC ”
• Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. (2017, neutral): “10 14 (13) 3 (11) 2 (7) 6 (18) 2 (29) 2 (50) 0 0 LDH .”
• Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012, background): “The immunohistochemical expression of MYC and/or BCL2 or both (double expressors) is only partly correlated with genetic abnormalities, but the concurrent expression of MYC and BCL2 is usually associated with a poor outcome [17–19].”
• Discovery and Characterization of Super-Enhancer Associated Dependencies in Diffuse Large B-Cell Lymphoma (2013, neutral): “In recent studies, a newly defined subset of “double-hit” DLBCLs which overexpress MYC in association with BCL2 also have an unfavorable outcome (Hu et al., 2013; Johnson et al., 2012).”
• The 2016 revision of the World Health Organization classification of lymphoid neoplasms. (2016, neutral): “In several but not all studies, the double-expressor lymphomas have a worse outcome than other DLBCL, NOS but they are not as aggressive as the HGBL, with rearrangements of MYC and BCL2 and/or BCL6.(69,70) These observations have suggested that double expression of MYC and BCL2 proteins without gene”
• Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (2019, background): “Higher treatment failure rates are observed in poor-risk subgroups, including activated B-cell–like (ABC) and MYC/ BCL2 double-expressor lymphomas (DEL).(5,6) Platinum-based salvage therapy followed by high-dose chemotherapy and autologous stem-cell transplantation (ASCT) can cure 30%-40% of patient”